RxDoctor Payments Data

Nelson Mane, MD

Internal Medicine · Tampa, FLNPI 1568520971

Payments from drug & device makers

$767in general payments, 2019–2025

Across 18 payments — averaging $42.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$293
  • Amgen$149
  • GSK$122
  • Pfizer$56
  • Currax Pharmaceuticals LLC$25
  • Lilly USA, LLC$24
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$74297%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$895,666
Medicare patients
1,308
Services billed
8,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$166,781
JardianceEmpagliflozin120$127,847
FarxigaDapagliflozin Propanediol109$64,032
XareltoRivaroxaban71$49,578
JanuviaSitagliptin Phosphate33$42,991
OzempicSemaglutide29$42,094
EntrestoSacubitril/Valsartan45$37,686
ProcritEpoetin Alfa48$36,377
VraylarCariprazine Hcl14$25,305
OxycontinOxycodone Hcl22$24,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,322
NexlizetBempedoic Acid/Ezetimibe15$14,378
MounjaroTirzepatide12$11,999
LokelmaSodium Zirconium Cyclosilicate11$10,258
Tresiba Flextouch U-100Insulin Degludec20$10,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$166,781217 claims
Boehringer IngelheimJardiance$21$127,847120 claims
Johnson & JohnsonXarelto, Procrit$293$85,956119 claims
NovartisEntresto$17$37,68645 claims
GSKTrelegy Ellipta, Breo Ellipta$122$31,98939 claims
AbbVieVraylar$18$25,30514 claims
Lilly USA, LLCMounjaro$24$11,99912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →